ACUTE TREATMENT OF MIGRAINE

Trudhesa (formally, INP 104) was first approved for acute treatment of migraine on September 2, 2021. Trudhesa uses nasal delivery of DHE (Dihydroergotamine mesylate), 0.725mg per spray. Dihydroergotamine mesylate is a well-established migraine treatment with more than 70 years of therapeutic use. Trudhesa, is advanced because it bypasses the gastrointestinal absorption to provides a quicker delivery of DHE into the bloodstream through vascular -rich upper nasal space. Trudhesa is not indicated for the preventive treatment of migraine or for the management of hemiplegic or basilar migraine. This approval provides another abortive option for a patient to add to their migraine toolbox. Please call The Manhattan Center for Headache & Neurology to speak with one of our caring providers about questions regarding this new advancement in acute migraine treatment!